Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Masaki Mori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8093-8848; OpenAlex author ID A5059433142. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells. Last author DOI 10.21873/anticanres.17974↗
  2. [A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy]. Co-author PMID 25731236↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuhki Yokoyama · 1 shared paper, 2026 · strength 0.25
  2. Tomofumi Ohashi · 1 shared paper, 2014 · strength 0.04
  3. Tadafumi Asaoka · 1 shared paper, 2014 · strength 0.04
  4. Yuichiro Doki · 1 shared paper, 2014 · strength 0.04
  5. Hidetoshi Eguchi · 1 shared paper, 2014 · strength 0.04
  6. Yoshito Tomimaru · 1 shared paper, 2014 · strength 0.04
  7. Shigeru Marubashi · 1 shared paper, 2014 · strength 0.04
  8. Hiroaki Nagano · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.